small win: dose escalation stopped being a problem at week 55
small win: dose escalation stopped being a problem at week 55, logged the same way every week so the comparison is at least internally fair. Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish. It is a triple…
Yes — the comparison threads are apples to oranges and they generate more heat than anything else here.
That is body weight change, not fat mass. The trials report the first and people quote it as the second.
Sceptical of the extrapolation. Forty-eight weeks does not tell you about seventy-two, and the curve shape is exactly what is unknown.
Trial names corrected in the title. The phase 3 programme and the phase 2 readout are not the same thing.
research-use-only material is not approved for human use, full stop
research-use-only material is not approved for human use, full stop
Disagree with this specific inference. A 48-week readout does not tell you the shape of the curve after it.
Has anyone posted an independent test on this compound recently?
Watched heart rate on a wearable across twelve weeks because the threads said to. It moved a little and I have no idea whether that means anything.